Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Cumberland Pharmaceuticals Announces New Product Addition With Hepatorenâ„¢ (ifetroban) Injection

April 19, 2011 By Bio-Medicine.Org

NASHVILLE, Tenn., April 19, 2011 /PRNewswire/ — Cumberland
Pharmaceuticals Inc.
(NASDAQ:
CPIX
), a specialty pharmaceutical company focused on hospital
acute care and gastroenterology markets, today announced that it
has entered into an agreement to acquire the rights to ifetroban, a
new Phase II development product. The Company has initiated
clinical development under the brand name Hepatoren™
(ifetroban) Injection and is evaluating the product for the
treatment of critically ill hospitalized patients suffering from
Hepatorenal Syndrome (HRS). Cumberland also has commenced
manufacturing and received clearance from the U.S. Food and Drug
Administration (FDA) for its investigational new drug (IND)
submission associated with the product.

Hepatorenal Syndrome is a life-threatening condition involving
progressive kidney failure. Approximately 450,000 patients in the
United States suffer from medical conditions that make them
susceptible to cirrhosis and a subset of these patients develop HRS
every year. Decrease in kidney function causes nitrogen-containing
waste products to build up in the bloodstream and ifetroban may
improve renal function in HRS patients by increasing low renal
blood flow. There is currently no drug approved for the treatment
of HRS in the United States.

Cumberland’s acquisition of the ifetroban program includes
rights to an extensive clinical database and non-clinical data
package as well as manufacturing processes, know-how and
intellectual property related to the product. Ifetroban, an active
thromboxane receptor antagonist, was initially developed by
Bristol-Myers Squibb (BMS) for significant cardiovascular
indications. BMS conducted extensive preclinical and clinical
studies, including seven Phase II trials for its own target
indications, and eventually donated the entire program to
Vanderbilt University. Researchers at Vanderbilt’s D

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech